The efficacy and safety of cangrelor in single vessel vs multivessel percutaneous coronary intervention: Insights from CHAMPION PHOENIX.
Celina M YongVandana SundaramFreddy AbnousiChristoph B OlivierJaden YangGregg W StonePhilippe G StegC Michael GibsonChristian W HammMatthew J PriceEfthymios N DeliargyrisJayne PratsHarvey D WhiteRobert A HarringtonDeepak L BhattKenneth W Mahaffeynull nullPublished in: Clinical cardiology (2019)
In patients undergoing SV- or MV-PCI, cangrelor was associated with similar relative risk reductions in ischemic complications and no increased risk of significant bleeding compared with clopidogrel, which highlights the expanding repertoire of options for use in complex PCI.
Keyphrases
- percutaneous coronary intervention
- st segment elevation myocardial infarction
- st elevation myocardial infarction
- acute coronary syndrome
- antiplatelet therapy
- patients undergoing
- acute myocardial infarction
- coronary artery disease
- coronary artery bypass grafting
- atrial fibrillation
- coronary artery bypass
- risk factors
- ischemia reperfusion injury
- left ventricular
- high throughput sequencing
- oxidative stress